Is there a role for anti-IL6 therapy in SSc-associated ILD?

There may be a role for IL-6 inhibition for the treatment of ILD in scleroderma, but this has not been fully explored yet in clinical trials. However, the Phase II and Phase III studies of tocilizumab both suggested stabilization of FVC compared to the placebo arm. The Phase III faSScinate study inc...